The Food and Drug Administration recently approved a new antibiotic into the arsenal for treating serious acute bacterial skin and skin structure infections (ABSSSI).

Its called delafloxacin and goes by the trade name, Baxdela and its manufactured by Melinta Therapeutics.

Assistant Professor of Medicine, David Geffen School of Medicine at UCLA, James McKinnell, M.D. joined me to discuss the importance of this approval.